Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Receivables for the year ending December 31, 2023: USD 5.42 M

Biomm S.A. Receivables is USD 5.42 M for the year ending December 31, 2023, a 12.70% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Biomm S.A. Receivables for the year ending December 31, 2022 was USD 4.81 M, a -2.71% change year over year.
Biomm S.A. Receivables for the year ending December 31, 2021 was USD 4.95 M, a 25.63% change year over year.
Biomm S.A. Receivables for the year ending December 31, 2020 was USD 3.94 M, a 219.74% change year over year.
Biomm S.A. Receivables for the year ending December 31, 2019 was USD 1.23 M, a 669.83% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years